Display options
Cite
Corzo C, Griffin PR. Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity. Diabetes Metab J. 2013;37(6):395-403doi: 10.4093/dmj.2013.37.6.395.
Corzo, C., & Griffin, P. R. (2013). Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity. Diabetes & metabolism journal, 37(6), 395-403. https://doi.org/10.4093/dmj.2013.37.6.395
Corzo, Cesar, and Griffin, Patrick R. "Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity." Diabetes & metabolism journal vol. 37,6 (2013): 395-403. doi: https://doi.org/10.4093/dmj.2013.37.6.395
Corzo C, Griffin PR. Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity. Diabetes Metab J. 2013 Dec;37(6):395-403. doi: 10.4093/dmj.2013.37.6.395. PMID: 24404510; PMCID: PMC3881323.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab J. 2013 Dec;37(6):395-403. doi: 10.4093/dmj.2013.37.6.395.

Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity.

Diabetes & metabolism journal

Cesar Corzo, Patrick R Griffin

Affiliations

  1. Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA.

PMID: 24404510 PMCID: PMC3881323 DOI: 10.4093/dmj.2013.37.6.395

Abstract

Adipose tissue, which was once viewed as a simple organ for storage of triglycerides, is now considered an important endocrine organ. Abnormal adipose tissue mass is associated with defects in endocrine and metabolic functions which are the underlying causes of the metabolic syndrome. Many adipokines, hormones secreted by adipose tissue, regulate cells from the immune system. Interestingly, most of these adipokines are proinflammatory mediators, which increase dramatically in the obese state and are believed to be involved in the pathogenesis of insulin resistance. Drugs that target peroxisome proliferator-activated receptor-γ have been shown to possess anti-inflammatory effects in animal models of diabetes. These findings, and the link between inflammation and the metabolic syndrome, will be reviewed here.

Keywords: Diabetes; Hypoglycemic agents; Metabolic disorders; Metabolic syndrome; PPAR gamma; Protein processing, post-translational; Receptors, cytoplasmic and nuclear; Review; Synthetic ligands; Thiazolidinediones

References

  1. Metabolism. 2001 Nov;50(11):1294-300 - PubMed
  2. Cell. 1992 Mar 6;68(5):879-87 - PubMed
  3. J Clin Invest. 2007 Jan;117(1):175-84 - PubMed
  4. Mutat Res. 2000 Mar 17;448(2):121-38 - PubMed
  5. Circulation. 2004 Feb 3;109(4):551-6 - PubMed
  6. Nature. 2011 Sep 04;477(7365):477-81 - PubMed
  7. Development. 2000 Jun;127(11):2269-82 - PubMed
  8. Nature. 2007 Jun 28;447(7148):1116-20 - PubMed
  9. J Biol Chem. 2007 Nov 30;282(48):35279-92 - PubMed
  10. Biochem Biophys Res Commun. 1999 Nov;265(1):265-71 - PubMed
  11. Circulation. 2005 Oct 25;112(17):2735-52 - PubMed
  12. Diabetes Care. 2004 Jan;27(1):256-63 - PubMed
  13. Cell Mol Life Sci. 2004 Feb;61(4):393-416 - PubMed
  14. J Biol Chem. 2003 Nov 14;278(46):45777-84 - PubMed
  15. J Pediatr. 1984 Mar;104(3):327-36 - PubMed
  16. Nature. 2005 Sep 29;437(7059):759-63 - PubMed
  17. Nat Rev Drug Discov. 2004 Nov;3(11):950-64 - PubMed
  18. J Clin Endocrinol Metab. 2006 Sep;91(9):3349-54 - PubMed
  19. Diabetes Care. 1996 Apr;19(4):396-400 - PubMed
  20. Endocrinology. 2002 Jun;143(6):2376-84 - PubMed
  21. Nature. 1997 Oct 9;389(6651):610-4 - PubMed
  22. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):692-3 - PubMed
  23. Nature. 1992 Aug 27;358(6389):771-4 - PubMed
  24. Curr Opin Struct Biol. 2007 Dec;17(6):699-705 - PubMed
  25. BMC Endocr Disord. 2011 May 26;11:11 - PubMed
  26. Diabetes Care. 2001 Jul;24(7):1226-32 - PubMed
  27. Curr Opin Pharmacol. 2010 Dec;10(6):684-91 - PubMed
  28. Diabetologia. 2012 Oct;55(10):2565-2582 - PubMed
  29. J Clin Invest. 2003 Dec;112(12):1821-30 - PubMed
  30. Diabetes. 2002 Dec;51(12):3391-9 - PubMed
  31. Annu Rev Immunol. 2009;27:451-83 - PubMed
  32. Nature. 2010 Jul 22;466(7305):451-6 - PubMed
  33. J Biol Chem. 1997 Jan 24;272(4):2551-8 - PubMed
  34. Nature. 2011 Nov 20;480(7375):104-8 - PubMed
  35. Mol Endocrinol. 2008 Mar;22(3):539-45 - PubMed
  36. Arch Physiol Biochem. 2009 Oct;115(4):227-39 - PubMed
  37. Annu Rev Pharmacol Toxicol. 1996;36:615-58 - PubMed
  38. PLoS One. 2011;6(10):e26947 - PubMed
  39. PPAR Res. 2009;2009:925309 - PubMed
  40. J Endocrinol. 2006 Mar;188(3):467-80 - PubMed
  41. Diabetologia. 2007 Dec;50(12):2562-71 - PubMed
  42. Nature. 1990 Oct 18;347(6294):645-50 - PubMed
  43. Nat Med. 2001 Oct;7(10):1138-43 - PubMed
  44. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:93-7 - PubMed
  45. Biochem J. 2001 Aug 1;357(Pt 3):593-615 - PubMed
  46. J Cell Biol. 1966 Feb;28(2):303-32 - PubMed
  47. PLoS One. 2010 Jun 04;5(6):e10962 - PubMed
  48. Endocrinology. 2007 Dec;148(12):6047-53 - PubMed
  49. Acta Med Scand Suppl. 1988;723:135-41 - PubMed
  50. J Clin Invest. 2006 Mar;116(3):590-7 - PubMed
  51. Endocrinology. 2007 Oct;148(10):4548-56 - PubMed
  52. J Clin Invest. 2003 Dec;112(12):1796-808 - PubMed
  53. J Clin Invest. 2006 Jan;116(1):115-24 - PubMed
  54. Endocr J. 1999 Dec;46(6):795-801 - PubMed
  55. Drugs. 2002;62(10):1463-80 - PubMed
  56. Nucleic Acids Res. 2010 Nov;38(21):7458-71 - PubMed
  57. Annu Rev Med. 2005;56:45-62 - PubMed
  58. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7265-70 - PubMed

Publication Types

Grant support